Treatments targeting the SARS-CoV-2 spike protein span a wide range of strategies, from monoclonal antibodies and engineered decoy receptors to small-molecule entry blockers and experimental blood-filtering techniques, but most remain in preclinical or early clinical stages. The spike protein has emerged as much more than a viral doorknob: it actively drives inflammation, blood clotting, and immune disruption on its own, which is why researchers are pursuing therapies aimed not just at blocking infection but at neutralizing or clearing spike protein that lingers in the body after the acute phase of illness. The science is moving fast, and the gap between laboratory promise and proven bedside treatments remains significant.
Why the Spike Protein Itself Causes Damage
Understanding why so many treatment strategies exist requires understanding the spike protein’s multiple roles in causing harm. It is not simply a key that unlocks cells. Once the spike protein’s S1 subunit binds to ACE2 receptors on blood vessel walls, it triggers a cascade of endothelial damage: cells lining the microvasculature shift into a pro-inflammatory state, recruiting white blood cells and losing their natural blood-thinning surface molecules like thrombomodulin. This process also activates the complement system, a branch of innate immunity that amplifies inflammation and promotes platelet clumping. In laboratory experiments, blocking either ACE2 or complement was enough to halt spike-induced platelet aggregation.1Frontiers in Immunology. SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation
Animal studies reinforce this picture. When S1 protein was injected into mice engineered to carry human ACE2 receptors, their lungs showed thrombomodulin loss and increased von Willebrand factor within three days, followed by diffuse lung damage, fibrin deposits, and eventually fibrosis at seven days. Complement deposits on both vascular and lung tissue preceded the overt damage, suggesting complement activation is an early driver rather than a late bystander.2PubMed Central. SARS-CoV-2 spike protein induces lung endothelial cell dysfunction and thrombo-inflammation depending on the C3a/C3a receptor signalling
The spike protein also appears to hijack inflammatory signaling through Toll-like receptor 4 (TLR4), a receptor the immune system normally uses to detect bacterial components. Computational and laboratory studies suggest the spike binds TLR4 with high affinity, triggering the release of inflammatory cytokines and potentially increasing ACE2 expression on cell surfaces, which could paradoxically make cells more vulnerable to further spike binding.3PubMed Central. COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation This TLR4 pathway has also been implicated in brain inflammation: microglia, the brain’s immune cells, were activated by the S1 protein to produce a suite of inflammatory mediators through TLR4-dependent signaling.4PubMed Central. Exploring SARS-CoV-2 impact on blood-brain barrier and its composition: A review
Spike Protein and Abnormal Blood Clotting
One of the most clinically relevant mechanisms of spike protein harm involves its interaction with fibrinogen, the protein that forms the scaffolding of blood clots. When spike protein encounters fibrinogen in plasma, it creates structural changes in fibrin that make resulting clots denser, with thinner fibers, and far more resistant to the body’s normal clot-dissolving machinery. This fibrinolysis resistance has been observed across multiple independent research groups and may explain the “microclots” found in the blood of people with long COVID.
A 2024 study published in Nature found that incubating spike protein with fibrin delayed degradation by plasmin, the enzyme responsible for breaking down clots.5Nature. Fibrin drives thromboinflammation and neuropathology in COVID-19 Separately, researchers demonstrated that when spike protein S1 was added to healthy plasma, mass spectrometry revealed structural changes in both fibrinogen and complement protein C3, with the altered proteins becoming substantially resistant to enzymatic breakdown.6Bioscience Reports. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19 More recently, a study in Biochemistry showed that amyloid fibrils formed from a specific spike protein fragment (residues 685–701) incorporate into fibrin networks and create structures highly resistant to plasmin dissolution, proposing a concrete molecular mechanism for how spike contributes to persistent microclots.7PubMed Central. SARS-CoV‑2 Spike Protein Amyloid Fibrils Impair Fibrin Formation and Fibrinolysis
Persistence After Infection
These damage mechanisms matter well beyond the acute illness because spike protein and viral remnants can persist in the body for months. A study measuring SARS-CoV-2 antigens in plasma found that compared to pre-pandemic blood samples (where about 2% showed false-positive assay results), people who had recovered from COVID showed significantly elevated detection of viral antigens for over a year: roughly 13% prevalence at three to six months post-infection, dropping to about 11% at six to ten months, and still around 7% beyond ten months.8PubMed Central. Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection Broader reviews of the evidence have catalogued viral and RNA reservoirs detected in biopsy, blood, stool, and autopsy samples from people with long COVID, with persisting virus-specific immune responses serving as indirect evidence of ongoing antigen exposure.9PubMed Central. Insights into Persistent SARS-CoV-2 Reservoirs in Chronic Long COVID
This persistence is a key reason researchers are not satisfied with treatments that merely block initial infection. If spike protein hangs around in tissue reservoirs, therapies that can neutralize or clear it after the fact become just as important as those that prevent viral entry in the first place.
Monoclonal Antibodies and the Variant Escape Problem
Monoclonal antibodies that bind the spike protein were among the first targeted therapies for COVID-19. The concept is straightforward: lab-engineered antibodies latch onto the spike’s receptor-binding domain and physically prevent it from attaching to cells. Early combination therapies like REGN-COV2 (casirivimab/imdevimab) and the Lilly combination (bamlanivimab/etesevimab) worked well against the original virus and early variants, but the Omicron variant’s heavily mutated spike protein rendered most of them useless. Testing showed that REGN-COV2 and the Lilly combination lost all neutralizing activity against Omicron B.1.1.529, while tixagevimab/cilgavimab (Evusheld) retained partial but significantly reduced activity.10Nature Medicine. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
The search for broadly neutralizing antibodies continues. One approach targets conserved regions of the spike that mutate less frequently. An antibody called 553-49 was found to neutralize the Omicron variant through an unusual mechanism: rather than blocking receptor binding, it disassembles the spike trimer itself, pulling apart the three-lobed structure the virus needs to function.11PubMed Central. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer Another candidate, CR9, showed neutralizing activity across several Omicron subvariants including BA.1, BA.2, and BA.2.86, though it failed against the JN.1 subvariant, illustrating the continuing arms race between antibody design and viral evolution.12Signal Transduction and Targeted Therapy. A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
A newer structural study has identified antibodies that target a different vulnerability: the S2′ cleavage site that the host protease TMPRSS2 must cut for viral fusion to proceed. These antibodies block protease access rather than receptor binding, and because the S2′ region is more conserved across variants, they show broader neutralization potential.13Nature Structural & Molecular Biology. TMPRSS2-mediated coronavirus spike activation and inhibition
ACE2 Decoy Receptors
One way to sidestep the variant escape problem entirely is to use the virus’s own entry mechanism against it. ACE2 decoy receptors are engineered versions of the human ACE2 protein, modified to bind the spike much more tightly than normal ACE2 while stripped of their enzymatic activity so they do not affect blood pressure regulation. When these decoys flood the area around the virus, spike proteins bind to them instead of real cell-surface ACE2, neutralizing the virus before it can infect.
Early proof-of-concept work produced optimized ACE2 receptor traps fused to an antibody backbone for stability, achieving neutralization of both pseudotyped and authentic SARS-CoV-2 at concentrations in the tens to hundreds of nanograms per milliliter range.14PubMed Central. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 The critical advantage emerged with later variants: because any functional variant still has to bind ACE2 to infect cells, engineered ACE2 decoys retained neutralization activity against Omicron subvariants including XBB and BQ.1, which completely evade existing clinical monoclonal antibodies. An inhaled aerosol version has shown protection in animal models, opening the door to a non-invasive delivery route that concentrates the therapeutic exactly where the virus enters the body.15PubMed. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models
Blocking Viral Entry with TMPRSS2 Inhibitors
The virus does not just bind ACE2 and walk in. After initial attachment, the host enzyme TMPRSS2 must cut the spike at a specific site (the S2′ site at arginine 815) to trigger the membrane fusion machinery that lets the virus inject its genetic material. Blocking this cut with mutagenesis of that arginine site was enough to prevent infection across multiple cell lines and primary human cells.16PubMed Central. SARS-CoV-2 spike engagement of ACE2 primes S2′ site cleavage and fusion initiation
Two existing drugs, camostat and nafamostat, inhibit TMPRSS2 and saw early investigation during the pandemic. But researchers have since developed far more potent alternatives. A class of small-molecule inhibitors called ketobenzothiazoles showed dramatically improved activity: the lead compound, MM3122, inhibited TMPRSS2 at a concentration of 340 picomolar (roughly a thousand-fold more potent than camostat) and blocked viral entry into human lung cells at similarly low concentrations.17PubMed Central. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells Other groups have taken computational approaches, screening large molecular databases for TMPRSS2 inhibitors and identifying multiple novel chemical starting points for drug development.18PubMed Central. Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19 Because TMPRSS2 is a human enzyme rather than a viral protein, it does not mutate with new variants, making this approach inherently variant-proof.
Nasal Delivery of Neutralizing Antibodies
Delivering spike-targeting therapies directly to the nose and airways, where infection begins, is an appealing strategy for prevention. In a small clinical trial, volunteers who received a nasal spray containing the monoclonal antibody 35B5 had detectable antibody concentrations in their nasal mucus at both 12 and 24 hours, ranging from about 1 to 10 micrograms per milliliter. The antibody-rich nasal mucus neutralized pseudoviruses representing the original strain, Alpha, Beta, Delta, and Omicron variants at both time points, with 100% of samples showing protective activity.19Clinical Infectious Diseases. Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial
Preclinical work in mice has shown similar promise. Intranasal delivery of a neutralizing antibody provided at least ten hours of protection against pseudoviral infection, with neither the nasal cavity nor lungs showing signs of infection seven days later in treated animals.20bioRxiv. Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice This approach faces practical hurdles, including the need for repeated application and the challenge of maintaining therapeutic concentrations across the entire mucosal surface, but it represents one of the more immediately translatable prevention strategies.
Immunoadsorption for Clearing Circulating Spike
For people who already have spike protein circulating in their blood, some researchers are exploring ways to physically remove it. Immunoadsorption is a blood-filtering technique, similar to dialysis, that passes plasma through columns designed to capture specific antibodies or proteins. In a study of patients with ME/CFS triggered or worsened by COVID-19, immunoadsorption treatment nearly eliminated certain autoantibodies from the blood. Alongside the antibody removal, the procedure also significantly reduced circulating soluble spike protein and lowered levels of several pro-inflammatory cytokines including IL-4, IL-2, IL-1β, TNF, and IL-17A.21PubMed Central. Effect of immunoadsorption on clinical presentation and immune alterations in COVID-19-induced and/or aggravated ME/CFS
This approach is expensive, invasive, and available only at specialized centers, so it is not a practical option for most people. But it provides proof of concept that removing spike protein and associated inflammatory mediators from circulation is technically achievable, and it offers a starting point for developing less burdensome clearance techniques.
Autophagy-Based Clearance Strategies
A less invasive theoretical approach involves boosting the body’s own cellular recycling system. Autophagy is the process by which cells break down and dispose of damaged proteins, misfolded aggregates, and other intracellular debris. Researchers have proposed that enhancing autophagy could help clear accumulated spike protein from cells and tissues. A review exploring this concept discusses how fasting-induced autophagy and pharmacological agents like spermidine, resveratrol, rapamycin, and metformin could be deployed to upregulate this clearance pathway for spike-related pathology.22Endocrine and Metabolic Science. Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology
It is worth being clear-eyed about where this stands: the autophagy approach to spike clearance is largely theoretical and based on known mechanisms of these compounds in other contexts. No clinical trials have yet demonstrated that boosting autophagy actually reduces spike protein levels in people with long COVID or improves their symptoms. The biological rationale is plausible, but the therapeutic proof has not arrived yet.
Drug Repurposing Screens
Thousands of already-approved drugs have been screened for their ability to interfere with the spike-ACE2 interaction. One large screen of over 2,700 compounds from international regulatory agencies identified 56 that inhibited spike-ACE2 binding in a concentration-dependent manner. The most promising candidates, including thiostrepton, oxytocin, nilotinib, and hydroxycamptothecin, showed inhibition at concentrations in the 4 to 9 micromolar range.23Frontiers in Pharmacology. A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2 Ivermectin has also been studied in computational docking analyses showing it can bind the spike-ACE2 complex, but this work is purely computational and should not be confused with clinical efficacy evidence.24PubMed Central. Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2
A critical point about all drug repurposing results: showing that a molecule interferes with spike-ACE2 binding in a test tube or a computer simulation is very far from showing it works in a living person at safe doses. The concentrations needed to block the interaction in vitro may be unachievable in human blood without toxicity. These screens are starting points for drug development, not treatment recommendations.
Natural Compounds and Supplement Protocols
The supplement market has been flooded with products claiming to “detox” spike protein, and the evidence behind them ranges from genuinely interesting to essentially nonexistent. Two of the most frequently discussed natural compounds are quercetin and epigallocatechin gallate (EGCG, found in green tea).
Quercetin’s story is instructive about how early-stage science gets distorted. Computational docking studies suggest both EGCG and quercetin can bind to the spike glycoprotein structure, with EGCG showing stronger predicted binding.25PubMed Central. Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study However, when quercetin was actually tested in a lab binding assay, it completely failed to inhibit spike protein from binding to ACE2 at concentrations up to 300 millimolar, while an anti-spike antibody did so efficiently. Quercetin did show activity in reducing cell-cell fusion through what appears to be a different mechanism unrelated to blocking the spike-ACE2 interaction directly.26PubMed Central. Quercetin inhibits SARS-CoV-2 infection and prevents syncytium formation by cells co-expressing the viral spike protein and human ACE2 The gap between “a computer model predicted binding” and “it actually works” is enormous, and quercetin illustrates this perfectly.
A proposed “spike detoxification protocol” combining nattokinase, bromelain, and curcumin has circulated widely online. Its proponents openly state that no large-scale clinical trials have been completed and that no therapeutic claims can be made until they are. The protocol was devised based on the known anti-inflammatory and anticoagulant properties of these compounds and their theoretical potential to degrade spike protein, but the authors themselves call for rigorous placebo-controlled testing before drawing conclusions.27PubMed Central. Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination Taking supplements with anticoagulant properties without medical supervision carries its own risks, particularly for people already on blood thinners.
Measuring Spike Protein in the Body
One practical challenge in developing and validating any spike-clearing therapy is actually measuring how much spike protein is present before and after treatment. Standard clinical tests were not designed for this. Researchers have developed ultrasensitive assays that can detect both spike and nucleocapsid proteins simultaneously in blood, achieving detection limits in the femtogram-per-milliliter range, which is roughly a trillion-fold more sensitive than a basic antibody test.28PubMed Central. Simultaneous detection of the spike and nucleocapsid proteins from SARS-CoV-2 based on ultrasensitive single molecule assays
Saliva-based detection has also advanced. An electrochemical sensor using magnetic beads and gold nanoparticles conjugated to ACE2 peptides achieved a detection limit for spike protein in saliva at the attogram-per-milliliter level, which is extraordinarily sensitive and could enable non-invasive monitoring.29PubMed Central. COVID-19 diagnosis by SARS-CoV-2 Spike protein detection in saliva using an ultrasensitive magneto-assay based on disposable electrochemical sensor These tools remain largely in the research setting, but their development is essential for the field: you cannot prove that a treatment clears spike protein if you cannot precisely measure spike protein levels before and after.
Peptide-Based Therapies in the Pipeline
A more experimental approach involves designing short synthetic peptides that compete with the virus for its receptor. SPIKENET (SPK) is a 15-amino-acid synthetic peptide designed to target the ACE2 receptor-binding domain of the spike protein, physically blocking attachment. In mouse studies using a coronavirus model, SPK reversed severe inflammation, tissue swelling, oxidative stress, and prevented animal death. It also protected against multi-organ damage in both acute infection and a long-term post-infection model. The peptide additionally blocked binding of spike proteins from all tested SARS-CoV-2 variants.30PubMed Central. SPIKENET: An Evidence-Based Therapy for Long COVID These results are still in animals, but peptide therapeutics have the advantage of being relatively cheap to manufacture and easy to modify as new variants emerge.
The broader landscape of spike protein therapeutics reflects a pattern common in medicine after a major new disease: a burst of creative approaches, many of which show genuine promise in the lab, followed by a long and expensive process of testing them in people. For anyone hoping for a proven treatment that specifically targets and clears persistent spike protein, the honest assessment is that the field is not there yet. The most advanced approaches, like ACE2 decoys and next-generation monoclonal antibodies, are closest to clinical application, while many of the supplements and repurposed drugs marketed to the public today rest on a much thinner evidence base than their sellers typically acknowledge.